• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Deutsche Bank ADR Virtual Investor Conference: Presentations Now Available for Online Viewing

    11/5/25 8:35:00 AM ET
    $BLTE
    $COE
    $HCM
    $LOT
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Other Consumer Services
    Real Estate
    Get the next $BLTE alert in real time by email

    NEW YORK, Nov. 05, 2025 (GLOBE NEWSWIRE) -- Virtual Investor Conferences, the leading proprietary investor conference series, today announced the presentations from the Depositary Receipts Virtual Investor Conference ("dbVIC") held November 4th are now available for online viewing.

    VIEW PRESENTATIONS HERE

    The company presentations will be available 24/7 for 90 days. Investors, advisors, and analysts may download investor materials from the company's resource section.

    November 4th Company Presentations

    HUTCHMED (China) Limited(AIM: HCM, NASDAQ:HCM, and HKEX:13)
    First Pacific Company Ltd((HKEX: 142, OTC:FPAFY)
    Viomi Technology Co., Ltd(NASDAQ:VIOT)
    Epiroc AB((Nasdaq Stockholm: EPIA, OTC:EPOAY)
    Yiren Digital Ltd.(NYSE:YRD)
    Belite Bio, Inc (NASDAQ:BLTE)
    Deutsche Lufthansa AG((FRA: LHA, OTCQX:DLAKY)
    Lotus Technology Inc(NASDAQ:LOT)
    51Talk Online Education Group(NYSE:COE)
    Radiopharm Theranostics Ltd(NASDAQ:RADX, ASX: RAD))
    Repsol S.A((BME: REP, OTCQX:REPYY)
      

    To facilitate investor relations scheduling and to view a complete calendar of Virtual Investor Conferences, please visit www.virtualinvestorconferences.com.

    About Virtual Investor Conferences®

    Virtual Investor Conferences (VIC) is the leading proprietary investor conference series that provides an interactive forum for publicly traded companies to seamlessly present directly to investors.

    Providing a real-time investor engagement solution, VIC is specifically designed to offer companies more efficient investor access. Replicating the components of an on-site investor conference, VIC offers companies enhanced capabilities to connect with investors, schedule targeted one-on-one meetings and enhance their presentations with dynamic video content. Accelerating the next level of investor engagement, Virtual Investor Conferences delivers leading investor communications to a global network of retail and institutional investors.

    Media Contact: 

    OTC Markets Group Inc. +1 (212) 896-4428, [email protected]

    Virtual Investor Conferences Contact:

    John M. Viglotti

    SVP Corporate Services, Investor Access

    OTC Markets Group

    (212) 220-2221

    [email protected]



    Primary Logo

    Get the next $BLTE alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $BLTE
    $COE
    $HCM
    $LOT

    CompanyDatePrice TargetRatingAnalyst
    Belite Bio Inc
    $BLTE
    12/2/2025$194.00Neutral → Outperform
    Mizuho
    Belite Bio Inc
    $BLTE
    11/24/2025$154.00Overweight
    Cantor Fitzgerald
    Belite Bio Inc
    $BLTE
    11/20/2025$105.00Neutral
    Mizuho
    HUTCHMED (China) Limited
    $HCM
    9/22/2025$13.75Equal-Weight → Underweight
    Morgan Stanley
    HUTCHMED (China) Limited
    $HCM
    5/13/2025Buy → Hold
    HSBC Securities
    Radiopharm Theranostics Limited
    $RADX
    3/12/2025$15.00Buy
    B. Riley Securities
    Belite Bio Inc
    $BLTE
    12/14/2023$60.00Buy
    Maxim Group
    HUTCHMED (China) Limited
    $HCM
    11/24/2023Hold → Buy
    Deutsche Bank
    More analyst ratings

    $BLTE
    $COE
    $HCM
    $LOT
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Yiren Digital Wins "Technology Innovation Leadership Award for Listed Companies" at the 23rd China's Financial Annual Champion Awards

    BEIJING, Dec. 11, 2025 /PRNewswire/ -- Yiren Digital Ltd. (NYSE:YRD) ("Yiren Digital" or the "Company"), a leading Fintech company specializing in digital consumer lending, insurance and financial technology innovation across China and Southeast Asia, today announced it has been awarded the "Technology Innovation Leadership Award for Listed Companies" at the 23rd China's Financial Annual Champion Awards. The award was presented during the 2025 China Financial Annual Conference, held in Beijing and co-hosted by the China Stock Exchange Executive Council and the leading financial media Hexun.com. The conference, themed "Charting a Breakthrough for China's Economy," brought together over twent

    12/11/25 2:40:00 AM ET
    $YRD
    Finance: Consumer Services
    Finance

    51Talk Online Education Group Announces New Share Repurchase Program

    SINGAPORE, Dec. 8, 2025 /PRNewswire/ -- 51Talk Online Education Group ("51Talk", or the "Company") (NYSE:COE), a global online education platform with core expertise in English education, today announced that its board of directors has authorized a new share repurchase program under which the Company may repurchase up to US$10 million worth of its shares (including American Depositary Shares) over the next 12 months, ending on December 7, 2026. The share repurchases may be effected from time to time on the open market at prevailing market prices, in privately negotiated transactions, in block trades and/or through other legally permissible means, depending on market conditions, and will be

    12/8/25 6:35:00 AM ET
    $COE
    Other Consumer Services
    Real Estate

    51Talk Online Education Group Announces Third Quarter 2025 Results

    SINGAPORE, Dec. 8, 2025 /PRNewswire/ -- 51Talk Online Education Group ("51Talk" or the "Company") (NYSE American: COE), a global online education platform with core expertise in English education, announced its unaudited results for the third quarter ended September 30, 2025. Third Quarter 2025 Financial and Operating Highlights Gross billings[1] for the third quarter of 2025 were US$40.5 million, a 104.6% growth from US$19.8 for the third quarter of 2024.Net revenues for the third quarter of 2025 were US$26.3 million, an 87.5% increase from US$14.0 million for the third quarter of 2024.The number of quarterly active students with attended lesson consumption for the third quarter of 2025 wa

    12/8/25 6:30:00 AM ET
    $COE
    Other Consumer Services
    Real Estate

    $BLTE
    $COE
    $HCM
    $LOT
    SEC Filings

    View All

    SEC Form SCHEDULE 13G filed by Belite Bio Inc

    SCHEDULE 13G - BELITE BIO, INC (0001889109) (Subject)

    12/10/25 4:30:21 PM ET
    $BLTE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form 20-F/A filed by Radiopharm Theranostics Limited

    20-F/A - Radiopharm Theranostics Ltd (0001949257) (Filer)

    12/10/25 6:18:17 AM ET
    $RADX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 6-K filed by 51Talk Online Education Group

    6-K - 51Talk Online Education Group (0001659494) (Filer)

    12/8/25 6:50:34 AM ET
    $COE
    Other Consumer Services
    Real Estate

    $BLTE
    $COE
    $HCM
    $LOT
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Belite Bio upgraded by Mizuho with a new price target

    Mizuho upgraded Belite Bio from Neutral to Outperform and set a new price target of $194.00

    12/2/25 8:17:09 AM ET
    $BLTE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Cantor Fitzgerald resumed coverage on Belite Bio with a new price target

    Cantor Fitzgerald resumed coverage of Belite Bio with a rating of Overweight and set a new price target of $154.00

    11/24/25 8:35:36 AM ET
    $BLTE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Mizuho initiated coverage on Belite Bio with a new price target

    Mizuho initiated coverage of Belite Bio with a rating of Neutral and set a new price target of $105.00

    11/20/25 8:06:38 AM ET
    $BLTE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $BLTE
    $COE
    $HCM
    $LOT
    Leadership Updates

    Live Leadership Updates

    View All

    Viomi Technology Co., Ltd Appoints Malaysian Pop Star Shila Amzah as Brand Ambassador and Announces New AI Water Purifier Launch in Malaysia

    GUANGZHOU, China, Oct. 20, 2025 (GLOBE NEWSWIRE) -- Viomi Technology Co., Ltd ("Viomi" or the "Company") (NASDAQ:VIOT), a leading technology company for home water solutions in China, today announced the appointment of renowned Malaysian singer Ms. Shila Amzah as its brand ambassador in Malaysia. Ms. Amzah will join Viomi for a product launch event in Malaysia on October 30, where the Company will unveil its new AI water purifier, INNO, designed to bring a smarter and safer drinking water lifestyle to local households. Mr. Xiaoping Chen, Founder and CEO of Viomi, commented: "We are thrilled to welcome Ms. Shila Amzah as our brand ambassador in Malaysia. Together, at our upcoming product

    10/20/25 9:00:28 AM ET
    $VIOT
    Consumer Electronics/Appliances
    Consumer Discretionary

    HUTCHMED Announces Appointment of Independent Non-executive Director and Member of Board Committee

    HONG KONG and SHANGHAI and FLORHAM PARK, N.J., Oct. 14, 2025 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited ("HUTCHMED" or the "Company") (Nasdaq/AIM:​HCM, HKEX:​13) today announces that Professor Tan Shao Weng, Daniel (Chen Shaowen) is appointed as an Independent Non-executive Director and a member of the Technical Committee of the Company with effect from October 15, 2025. Professor Tan, aged 47, has over 20 years of experience in oncology, with his main research interests focusing on thoracic, head and neck malignancies, and drug development. He is the head of the Division of Clinical Trials and Epidemiological Sciences and a senior consultant in the Division of Medical Oncology at the N

    10/14/25 4:30:00 AM ET
    $HCM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    HUTCHMED Announces Appointment of Acting Chief Executive Officer

    HONG KONG and SHANGHAI and FLORHAM PARK, N.J, Aug. 25, 2025 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited ("HUTCHMED") (Nasdaq/AIM:​HCM; HKEX:​13) today announces that Dr Weiguo Su, an Executive Director of the Company, will take a leave of absence from his duties as Chief Executive Officer due to health reasons. In light of this, the Board of Directors has appointed Mr Johnny Cheng, an Executive Director and Chief Financial Officer of the Company, as Acting Chief Executive Officer with immediate effect, in addition to his role as Chief Financial Officer. Dr Dan Eldar, Chairman and Non-executive Director, said, "The Board expresses its full support for Dr Su and wishes him a speedy recover

    8/24/25 8:20:00 PM ET
    $HCM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $BLTE
    $COE
    $HCM
    $LOT
    Financials

    Live finance-specific insights

    View All

    51Talk Online Education Group Announces Third Quarter 2025 Results

    SINGAPORE, Dec. 8, 2025 /PRNewswire/ -- 51Talk Online Education Group ("51Talk" or the "Company") (NYSE American: COE), a global online education platform with core expertise in English education, announced its unaudited results for the third quarter ended September 30, 2025. Third Quarter 2025 Financial and Operating Highlights Gross billings[1] for the third quarter of 2025 were US$40.5 million, a 104.6% growth from US$19.8 for the third quarter of 2024.Net revenues for the third quarter of 2025 were US$26.3 million, an 87.5% increase from US$14.0 million for the third quarter of 2024.The number of quarterly active students with attended lesson consumption for the third quarter of 2025 wa

    12/8/25 6:30:00 AM ET
    $COE
    Other Consumer Services
    Real Estate

    51Talk Online Education Group to Report Third Quarter 2025 Financial Results on Monday, December 8, 2025

    Earnings Call Scheduled for 8:00 a.m. ET on December 8, 2025 SINGAPORE, Dec. 3, 2025 /PRNewswire/ -- 51Talk Online Education Group ("51Talk", or the "Company") (NYSE:COE), a global online education platform with core expertise in English education, today announced that it will report its unaudited financial results for the third quarter ended September 30, 2025 on Monday, December 8, 2025, before the open of U.S. markets. The Company's management will host an earnings conference call at 8:00 a.m. U.S. Eastern Time on December 8, 2025 (9:00 p.m. Singapore/Beijing/Hong Kong time on December 8, 2025). Dial-in details for the earnings conference call are as follows: United States Toll: 1-888-34

    12/3/25 4:01:00 PM ET
    $COE
    Other Consumer Services
    Real Estate

    New Hope for People Living with a Disease Once Deemed Untreatable: Belite Bio Announces Positive Topline Results from the Pivotal Global, Phase 3 DRAGON Trial of Tinlarebant in Adolescents with Stargardt Disease

    Tinlarebant is the first therapeutic candidate to demonstrate clinical efficacy in a global Phase 3 trial for Stargardt disease, achieving a statistically significant p-value of 0.0033Tinlarebant met the primary efficacy endpoint, demonstrating clinical benefit by significantly reducing the lesion growth rate by 36% compared to placebo, as measured by retinal imagingTinlarebant was well tolerated throughout the trial Stargardt disease impacts more than 50,000 patients in the U.S. Belite Bio plans to file an NDA with the US FDA in 1H 2026Company will host a conference call and webcast today at 8:00 a.m. ET SAN DIEGO, Dec. 01, 2025 (GLOBE NEWSWIRE) -- Belite Bio, Inc (NASDAQ:BLTE) ("Belite

    12/1/25 6:00:00 AM ET
    $BLTE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $BLTE
    $COE
    $HCM
    $LOT
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13D/A filed by 51Talk Online Education Group

    SC 13D/A - 51Talk Online Education Group (0001659494) (Subject)

    12/17/24 4:07:04 PM ET
    $COE
    Other Consumer Services
    Real Estate

    Amendment: SEC Form SC 13G/A filed by Viomi Technology Co. Ltd

    SC 13G/A - Viomi Technology Co., Ltd (0001742770) (Subject)

    11/12/24 6:35:53 AM ET
    $VIOT
    Consumer Electronics/Appliances
    Consumer Discretionary

    SEC Form SC 13G filed by Lotus Technology Inc.

    SC 13G - Lotus Technology Inc. (0001962746) (Subject)

    11/12/24 6:07:58 AM ET
    $LOT
    Auto Manufacturing
    Industrials